Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts

Radiation Oncology

Theodoros Tsakiridis⁵  Gurmit Singh⁴  James Wright⁵  Gregory R Steinberg³  Jean-Claude Cutz⁴  Tom Farrell¹  Carrie Schultz²  Sarah N Hopmans⁴  Toran Sanli⁴  Yaryna Storozhuk⁵ 

[1] Department of Medical Physics and Applied Radiation Science, McMaster University, Hamilton, Ontario, Canada;Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada;Department of Medicine, McMaster University, Hamilton, Ontario, Canada;Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada;Department of Oncology, McMaster University, 699 Concession Street, Hamilton, Ontario, Canada, L8V 5C2

关键词: p21^cip1;    4-EBP1;    p53;    ATM;    Lung cancer;   

Others  :  1160845
DOI  :  10.1186/1748-717X-7-71

 received in 2012-01-11, accepted in 2012-04-08,  发布年份 2012

【 授权许可】

   
2012 Storozhuk et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bussink J, van der Kogel AJ, Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9:288-296.
• [2]Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C: PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009, 21:194-198.
• [3]Furic L, Livingstone M, Dowling RJ, Sonenberg N: Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses. Curr Oncol 2009, 16:59-61.
• [4]Wang L, Harris TE, Lawrence JC: Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 2008, 283:15619-15627.
• [5]Laplante M, Sabatini DM: mTOR signaling at a glance. J Cell Sci 2009, 122:3589-3594.
• [6]Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T: Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010, 78:221-229.
• [7]Shackelford DB, Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9:563-575.
• [8]Steinberg GR, Kemp BE: AMPK in Health and Disease. Physiol Rev 2009, 89:1025-1078.
• [9]Laplante M, Sabatini DM: An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009, 19:R1046-R1052.
• [10]Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al.: The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007, 9:218-224.
• [11]Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, Corbett T, Sur R, Cai W, Whelan T, Wright JR: Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J Thorac Oncol 2008, 3:716-722.
• [12]Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzalez-Suarez I, Wang S, Zhang J, Roti Roti JL, Gonzalo S: The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res 2011, 175:214-224.
• [13]Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP: Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 2009, 69:7644-7652.
• [14]Lavin MF, Gueven N: The complexity of p53 stabilization and activation. Cell Death Differ 2006, 13:941-950.
• [15]Olive PL, Banath JP: Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009, 76:79-90.
• [16]Fu X, Wan S, Lyu YL, Liu LF, Qi H: Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS ONE 2008, 3:e2009.
• [17]Sanli T, Storozhuk Y, Linher-Melville K, Bristow RG, Laderout K, Viollet B, Wright J, Singh G, Tsakiridis T: Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother Oncol 2012, 102:459-465.
• [18]Budanov AV, Karin M: p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134:451-460.
• [19]Smith J, Tho LM, Xu N, Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010, 108:73-112.
• [20]Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P: Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007, 6:789-801.
• [21]Li Y, Yang DQ: The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther 2010, 9:113-125.
• [22]King TD, Song L, Jope RS: AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol 2006, 71:1637-1647.
• [23]Sanli T, Liu C, Rashid A, Hopmans S, Tsiani E, Schultz C, Farrell T, Singh G, Wright J, Tsakiridis T: Lovastatin sensitizes lung cancer cells to ionizing radiation. Modulation of growth and tumour suppressor signalling pathways and induction of apoptosis. J Thorac Oncol 2011, 63:439-50.
• [24]Cam H, Easton JB, High A, Houghton PJ: mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell 2010, 40:509-520.
• [25]Sanli T, Storozhuk Y, Linher-Melville K, Bristow RG, Laderout K, Viollet B, Wright J, Singh G, Tsakiridis T: Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother Oncol 2012, 102(3):459-65.